On January 12, 2020, the expert committee of atopic dermatitis biotherapy of China Medical Equipment Association was established in Beijing. Atopic dermatitis is a kind of chronic inflammatory skin disease related to genetic allergy, which seriously affects the quality of life and mental health of patients. In recent years, the rapid development and application of new biotherapy at home and abroad has become a hot topic for doctors and patients. New biological agents provide a new choice for the treatment of refractory chronic inflammatory skin diseases (such as psoriasis, atopic dermatitis, etc.).

        In order to promote and summarize the research on the application of targeted biological agents in the treatment of moderate and severe atopic dermatitis, led by the dermatology and dermatology branch of China Medical Equipment Association and the dermatology center of Boao super hospital, the expert committee of atopic dermatitis biotherapy of Dermatology and dermatology branch of China Medical Equipment Association was established, aiming to carry out targeted biological agents in the treatment of atopic dermatitis Cardiac cooperation will provide a safe and reliable biological agent treatment plan for moderate and severe atopic dermatitis; the committee will promote the research plan of thousands of atopic dermatitis at the same time, provide clinical research data for real world research, and lay a foundation for the development of consensus among experts on atopic dermatitis biotherapy.

        Professor Zhang Xuejun, director of Institute of Dermatology, Fudan University, leader of Dermatology center of Boao hospital, former chairman of Asian Society of Dermatology and honorary chairman of Dermatology and venereal disease branch of Chinese Medical Association, served as chairman of Expert Committee; Professor Zhang Jianzhong, Peking University People's Hospital, Professor Zheng Jie, Ruijin Hospital Affiliated to Shanghai Jiaotong University Medical College and Xijing Medical College of Air Force Military Medical University Professor Wang Gang was appointed as the consultant of the Committee; Professor Zheng Min of the Second Affiliated Hospital of Zhejiang University Medical College, Professor Gao Xinghua of the First Affiliated Hospital of China Medical University, Professor Zhang Furen of Shandong Dermatology Hospital, Professor Yao Zhirong of Xinhua Hospital of Shanghai Jiaotong University Medical College and Professor Cui Yong of China Japan Friendship Hospital were appointed as the vice chairman of the Expert Committee; other members were from all over the country 35 well-known experts from all over the country served as members.

Group photo of all experts of biotherapy Expert Committee of atopic dermatitis

        Professor Zhang Xuejun pointed out that the skin medicine center of Hainan Boao super hospital, relying on the "minimalist examination and approval" policy of Boao Lecheng International Medical Tourism Pioneer Area, urgently needed to import licensed drugs and equipment, took the lead in carrying out the clinical application of imported biological agents in advance in China. At present, it has completed the diagnosis and treatment of hundreds of psoriasis, chronic urticaria and other skin diseases, and has made abundant achievements in the field of biological agents application Rich clinical experience. With the approval of the state, Hainan Boao super hospital has officially introduced IL-4 / 13 monoclonal antibody (dupilumab) for clinical application in advance, and completed the first clinical treatment in China in February 2019.

Professor Zhang Xuejun, director of Institute of Dermatology, Fudan University, leading expert of skin medicine center of Boao super hospital, former chairman of Asian Society of Dermatology and honorary chairman of Dermatology and venereal diseases branch of Chinese Medical Association

        Dupilumab is a humanized monoclonal antibody, targeting to block the signal pathway of IL-4 and IL-13, the key cytokines in atopic dermatitis, which can improve the degree of skin lesions and itching symptoms of atopic dermatitis patients quickly and permanently. It has been certified by the US Food and drug administration as a breakthrough therapy, with good long-term efficacy and safety.

        Dr. Gu Chengming, head of Sanofi's China Medical Department, said that dupilumab, a targeted biological agent, has been approved and listed by regulators in about 40 countries and regions around the world, including the United States, the European Union, Japan and other countries or regions where more than 65000 patients have benefited. Under the support of the real world data application pilot policy, Sanofi will fully support the pilot clinical application of biological agents in the Boao Lecheng International Medical Tourism pilot area; under the guidance of the expert committee, it will provide better treatment for the majority of adult patients with moderate and severe atopic dermatitis, and strive to be listed in China as soon as possible to benefit the patients.

Dr. Gu Chengming, head of Sanofi China Medical Department

        北京择它医疗科技有限公司总裁白满喜博士介绍特应性皮炎患者随访系统，为进一步规范化管理病人以及后续临床治疗提供数据支持。安徽医科大学第一附属医院汤华阳副教授做题为“IL-4/13单抗在特异性皮炎中的应用”报告，详细介绍了Dupilumab的应用进展；安徽医科大学第一附属医院盛宇俊副教授介绍了博鳌超级医院皮肤医学中心三个“全国首例”即生物制剂单抗“苏金”治疗银屑病、生物制剂Dupilumab 单抗治疗特应性皮炎以及医美项目Ultherapy奥赛拉超声治疗仪。

Dr. Bai Manxi

Associate Professor Tang Huayang

Associate Professor Sheng Yujun

        According to some data, 63% of patients with atopic dermatitis suffer from severe itching for more than 12 hours every day, 55% of patients suffer from sleep disturbance for 5-7 days every week. If atopic dermatitis is not effectively controlled, it will affect patients' mood and psychological state, leading to anxiety, depression and loneliness. Some patients have poor effect on conventional treatment, so new treatment methods are urgently needed. The establishment of the expert committee will further promote the treatment of adult moderate and severe atopic dermatitis with targeted biological agents, and effectively improve the level of diagnosis and treatment of atopic dermatitis in China. Thanks to the nine preferential policies of the international medical tourism Pioneer Area in Boao Lecheng, Hainan, and the urgent needs of the patients in the skin medical center of Boao super hospital, dupilumab monoclonal antibody was first introduced to treat adult moderate and severe atopic dermatitis, providing new safe and effective treatment options for the majority of patients.

        Boao super hospital dermatology center reservation Tel: 0898-62988043